Journal of Coronary Heart Diseases

Gut microbiota has been linked to a number of cardiovascular disorders in recent studies, with the study of gut microbiota and heart failure attracting particular interest. As a result, better understanding the function of gut microbiota in the formation and progression of heart failure would aid our understanding of the disease's pathophysiology and bring novel therapeutic options. Heart failure is a severe and fatal stage of many cardiovascular diseases, and it is an important aspect of global cardiovascular disease prevention and treatment

Arterio Venous Fistulas (AVFs) for Hemo Dialysis (HD) have significant difficulties. HD vascular access should be of sufficient quality to allow for repeated puncture and a high blood flow rate for high-efficiency dialysis with minimal problems. The dialysis crew must be well-versed in the operation of the AVF, and corrective interventions should be rare. The construction of an AVF produces conditions that allow blood to flow more freely through the veins. Fulfilling these requirements lessens the likelihood of turbulence and endothelium injury, which reduces the probability of stenosis

Ischemic Heart Disease (IHD) is a major source of morbidity and mortality around the world. Ischemic Cardio Myopathy (ICM) is a late consequence of IHD that manifests as dilated cardiomyopathy with decreased cardiac function that is not entirely due to coronary artery occlusion or ischemic injury. To evaluate the clinical, electrocardiographic and echocardiographic profile of patients it needs to present with ischemic cardiomyopathy. In this cross sectional observational study 100 patients of ischemic cardiomyopathy admitted in hospital or visited OPD in NICVD, Dhaka from March’15 to Sept’15 were studied.

Despite recent declines in age-standardized death rates in high-income countries, Cardio Vascular Diseases (CVD), such as Coronary Heart Disease (CHD) and stroke, and cancer remain the leading causes of morbidity and mortality in the United States, most Western and Eastern countries, and the world. The decreases in CVD and other non-communicable disease mortality and morbidity can be linked to a variety of reasons, including improvements in modifiable risk factors. Recent findings from a number of studies have revealed the benefits of low levels of modifiable risk factors, also known as cardiovascular health factors, for all-cause mortality and CVD mortality or morbidity. Several studies, mainly in the US, have shown that alarmingly few adults participating in cohort studies achieved the favourable levels of all 7 most frequently measured CVD risk factors: physically activity, normal blood pressure, glucose and total cholesterol levels, body weight, and healthy diet.

Thrombosis and inflammation may play a role in morbidity and mortality in coronavirus patients in 2019. Therapeutic-dose anticoagulation, we expected, would enhance outcomes in critically ill Covid-19 patients. Coronavirus disease 2019 (Covid-19) is linked to thrombosis and inflammation. Despite receiving standard-dose pharmacologic thromboprophylaxis, critically ill patients on Covid-19 are at increased risk of thrombosis. Systemic inflammation and coagulation activation indicators in circulation. As a result, inflammation and thrombosis may play a role in poor outcomes